• Price Momentum

    NXTS is trading near the bottom of its 52-week range and below its 200-day simple moving average.

  • Price change

    The price of NXTS shares has decreased $0.06 since the market last closed. This is a 4.38% drop.

  • Last closed at $1.31.

Key terms

About NXTS

Nexentis Technologies, Inc. is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. It delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. Its products include SpuDefender and FreshProtect. The SpuDefender is designed to control the post-harvest potato sprout. The FreshProtect is designed to control spoilage-creating microorganisms on post-harvest citrus fruit. The firm operates through the following segments: Pathogen prevention and prolong shelf life and N2O emissions Global warming solutions. Nexentis Technologies was founded by Nimrod Ben-Yehuda on April 1, 2009 and is headquartered in Ness Ziona, Israel.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $1.90M

    A market capitalization up to $300 million places NXTS in the micro-capitalization category.

Key terms

Smart score

Latest NXTS news

Jul 28, 2026 8:06am ET Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign Jul 07, 2026 8:25am ET Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative Jun 29, 2026 8:20am ET Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment Jun 22, 2026 8:22am ET Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery Jun 17, 2026 7:32am ET Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases May 18, 2026 9:30am ET Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development May 13, 2026 7:07am ET Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone May 05, 2026 7:32am ET Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™ Mar 13, 2026 9:15am ET Nexentis Technologies Inc. Launches New Corporate Website, Showcasing Innovative AI-Driven Biotech Platform

NXTS Financials

1-year income & revenue

  • NXTS total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Net income: -$4.05M (1Y), -$11.14M (Q2)

    Net Income increased 22.05% since last year and decreased 50.3% since last quarter.

  • Earnings per share: -$25.02 (1Y), -$13.66 (Q2)

    EPS increased 88.5% since last year and decreased 12.16% since last quarter.

Key terms

NXTS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NXTS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    NXTS's competitors are included in the Consumer Non-Durables sector and Household/Personal Care group

  • Market cap: $1.90M

    A market capitalization up to $300 million places NXTS in the micro-capitalization category.

Key terms